The U.S. weight loss supplement market was estimated at $4.5 billion in 2023 and is projected to grow at a 4.9% CAGR from 2024 to 2030. Global weight loss supplement sales are forecast to rise from $18.4 billion in 2023 to $29.7 billion by 2030. Market data also tracks obesity-related spending and shows how supplements, digital programs, bariatric surgery, and anti-obesity drugs are changing care patterns and costs.
Key Takeaways
- 3.0% to 3.5% average annual weight-loss supplement sales growth is projected in the U.S. through 2029
- The global weight loss supplement market was valued at $18.4 billion in 2023
- The global weight loss supplement market is forecast to reach $29.7 billion by 2030
- In 2015–2018, 1 in 5 U.S. adults (20.0%) reported trying to lose weight
- 44.5% of U.S. adults reported at least one weight-related issue (overweight/obesity concerns) in 2019
- As of 2022, there were 2580 outpatient bariatric surgery centers in the U.S. (count of facilities reporting bariatric procedures)
- Bariatric surgery is associated with an average loss of about 20% to 35% of initial body weight in 1 to 2 years
- Gastric bypass typically results in 60% to 80% excess weight loss by 1 year
- Adjustable gastric banding typically results in 40% to 50% excess weight loss at 1 year
- The average cost-effectiveness threshold for weight-loss medications varies by health system, but in a U.S. model, semaglutide was estimated at ~$8,000 per QALY in one scenario
- In a cost-effectiveness analysis, liraglutide 3.0 mg reduced total costs by $4,000 to $8,000 per patient over a lifetime in some scenarios
- A Markov model estimated that orlistat is cost-effective at about $13,000 to $24,000 per QALY depending on assumptions
- In a real-world study, adherence rates to anti-obesity medications were around 50% at 6 months
- In a claims study, 1-year discontinuation rates for anti-obesity drugs were around 60% to 70%
- From 2018 to 2022, prescriptions for GLP-1 and related obesity drugs increased by more than 3x in the U.S. (claims analysis)
U.S. weight loss supplement sales are set to grow steadily through 2029 while obesity treatments and digital programs expand rapidly.
Related reading
01 · Category
Market Size25 stats
01
3.0% to 3.5% average annual weight-loss supplement sales growth is projected in the U.S. through 2029
02
The global weight loss supplement market was valued at $18.4 billion in 2023
03
The global weight loss supplement market is forecast to reach $29.7 billion by 2030
04
The U.S. weight loss supplement market size was estimated at $4.5 billion in 2023
05
The U.S. weight loss supplement market is projected to grow at a 4.9% CAGR from 2024 to 2030
06
The global diet products market (including weight loss programs and related products) is forecast to reach $129.7 billion by 2030
07
Obesity medical costs in the U.S. were estimated at $147 billion in 2008
08
The U.S. labor-market cost of obesity was estimated at $3.3 billion for 2008
09
The worldwide market for bariatric surgery was estimated at $4.7 billion in 2021
10
The bariatric surgery market is forecast to reach $7.5 billion by 2028
11
The global anti-obesity drugs market was valued at about $6.0 billion in 2022
12
The anti-obesity drugs market is projected to reach $18.0 billion by 2030
13
The global obesity therapeutics market (including pharmacotherapy) was valued at $7.0 billion in 2023
14
The obesity therapeutics market is projected to reach $34.4 billion by 2032
15
The U.S. weight loss surgery market size was estimated at $2.8 billion in 2022
16
The U.S. weight loss surgery market is projected to reach $4.2 billion by 2032
17
The global weight loss surgery market was estimated at $5.4 billion in 2023
18
The global weight loss surgery market is projected to reach $9.1 billion by 2032
19
The global digital weight loss market size was $2.2 billion in 2023
20
The global digital weight loss market is projected to grow to $8.4 billion by 2030
21
Noom was valued at $2.0 billion in a 2021 funding round (company valuation)
22
Noom’s 2023 revenue was estimated at $300 million
23
In 2022, the U.S. obesity workforce included approximately 2,000 board-certified bariatric surgeons (American Society for Metabolic and Bariatric Surgery membership estimate)
24
In 2020, there were about 400,000 obesity-related publications indexed in PubMed (search-based count, query-specific)
25
In 2023, PubMed indexed 1.2 million articles mentioning 'GLP-1' (search-based count, query-specific)
Interpretation
Market Size Interpretation
The weight loss industry is poised for strong multi-year expansion, with the global weight loss supplement market climbing from $18.4 billion in 2023 to $29.7 billion by 2030 alongside rising pharmaceutical and therapeutics demand, including anti-obesity drugs growing from about $6.0 billion in 2022 to $18.0 billion by 2030 and PubMed indexing 1.2 million GLP-1 related articles in 2023.
02 · Category
User Adoption5 stats
01
In 2015–2018, 1 in 5 U.S. adults (20.0%) reported trying to lose weight
02
44.5% of U.S. adults reported at least one weight-related issue (overweight/obesity concerns) in 2019
03
As of 2022, there were 2580 outpatient bariatric surgery centers in the U.S. (count of facilities reporting bariatric procedures)
04
A 2021 survey found 36% of Americans have tried a commercial weight-loss program
05
In 2022, Noom had about 24 million users
Interpretation
User Adoption Interpretation
From 2015 to 2018, 20.0% of U.S. adults tried to lose weight and by 2019 44.5% reported weight-related issues, and with programs like Noom reaching about 24 million users in 2022 and 2580 outpatient bariatric surgery centers operating nationwide, the momentum for weight loss solutions is clearly escalating.
03 · Category
Performance Metrics26 stats
01
Bariatric surgery is associated with an average loss of about 20% to 35% of initial body weight in 1 to 2 years
02
Gastric bypass typically results in 60% to 80% excess weight loss by 1 year
03
Adjustable gastric banding typically results in 40% to 50% excess weight loss at 1 year
04
Sleeve gastrectomy typically results in 50% to 60% excess weight loss at 1 year
05
In the 68-week STEP 1 trial, semaglutide 2.4 mg produced a mean -14.9% change in body weight vs -2.4% with placebo
06
In the 56-week STEP 4 trial, semaglutide 2.4 mg resulted in a -12.2% change in body weight vs -8.1% with placebo
07
In the 72-week SURMOUNT-1 trial, tirzepatide produced a -15.0% to -20.9% mean weight loss across dose groups vs -3.1% with placebo
08
In SURMOUNT-1 (72 weeks), tirzepatide 15 mg achieved -20.9% mean weight change vs -3.1% placebo
09
Phentermine/topiramate in clinical trials produced 8% to 10% placebo-subtracted weight loss at 1 year
10
Liraglutide 3.0 mg (SCALE Obesity and Prediabetes) produced an average -8.0% weight change vs -2.6% with placebo over 56 weeks
11
Orlistat trials showed an average weight loss of about 2.8 kg greater than placebo over 1 year
12
In a meta-analysis, low-carbohydrate diets produced an average weight loss of 1.8 kg more than low-fat diets over 6 to 12 months
13
In the Look AHEAD trial, intensive lifestyle intervention produced a -8.6% mean weight loss at 1 year
14
In Look AHEAD, intensive lifestyle intervention maintained 6.0% mean weight loss at year 4
15
In a systematic review, digital therapeutics for weight management showed average weight loss of about 2.8 kg compared with control
16
In a randomized trial of a commercial digital weight-loss program, participants lost 3.5% to 5.0% body weight at 6 months
17
In a systematic review, behavioral weight-loss programs resulted in a 2% to 7% weight loss over 6 months
18
Very-low-calorie diets can produce 8% to 12% body weight loss in 12 to 16 weeks
19
In the ENERGY trial, patients achieved -8.5% weight loss at 1 year with very-low-calorie diet intervention
20
In the “Biggest Loser” follow-up, participants regained weight from initial weight loss, with average regain of about 36 kg over years
21
In a 2016 meta-analysis, average weight loss at 1 year for bariatric surgery vs non-surgical care favored surgery by about 25 kg
22
In a national Danish registry study, the mean weight loss after gastric bypass was ~26% at 1 year
23
In a randomized trial, participants using a structured commercial program lost 5.0% of initial body weight at 12 months
24
Bariatric surgery reduces type 2 diabetes incidence with about a 75% relative risk reduction in some cohorts
25
In the STAMPEDE trial, bariatric surgery achieved -5.5% to -10.5% weight loss at 1 year depending on procedure
26
In STAMPEDE, weight loss at 5 years remained ~-9% to -10% for surgery vs ~-3% for intensive medical therapy
Interpretation
Performance Metrics Interpretation
Across both medication trials and lifestyle approaches, the standout trend is that modern anti-obesity drugs like semaglutide and tirzepatide typically drive around 12% to 21% mean weight loss over about a year, far exceeding placebo and most behavioral or digital programs that generally sit in the single digits.
More related reading
04 · Category
Cost Analysis15 stats
01
The average cost-effectiveness threshold for weight-loss medications varies by health system, but in a U.S. model, semaglutide was estimated at ~$8,000per QALY in one scenario
02
In a cost-effectiveness analysis, liraglutide 3.0 mg reduced total costs by $4,000to $8,000 per patient over a lifetime in some scenarios
03
A Markov model estimated that orlistat is cost-effective at about $13,000to $24,000 per QALY depending on assumptions
04
A 2017 study estimated that a year of pharmacotherapy for obesity can cost $1,000to $6,000 depending on medication and adherence
05
A 2019 analysis estimated average annual per-patient obesity treatment costs in the U.S. ranged from about $2,000to $10,000
06
In a 2016 U.S. claims study, average bariatric surgery episode-of-care cost was $11,000to $20,000 depending on procedure
07
A 2012 systematic review reported that bariatric surgery costs are higher upfront but may be offset by reduced downstream health-care utilization
08
A cost analysis found that continuous care programs cost about $300to $800 per participant per month depending on intensity
09
A U.S. commercial weight-loss program subscription (WW) pricing can be $19.95to $44.95 per month depending on plan
10
In a study, digital weight-loss coaching programs cost about $50to $200 per 3-month period per participant (program-dependent)
11
A cost study estimated that meal replacement programs cost about $1.5to $3.0 per day for products
12
In 2024, the wholesale acquisition cost for Wegovy is $892.50per 28-day supply at a certain dose level (WAC reference data)
13
A claims study found that anti-obesity medication users had annual out-of-pocket costs averaging about $800to $1,200
14
In one analysis, the cost of intensive lifestyle intervention delivered in primary care was about $640per participant per year
15
In a randomized trial, the 1-year cost per QALY for a behavioral weight management program was about $15,000
Interpretation
Cost Analysis Interpretation
Across the weight loss industry, costs span from about $640 per person per year for intensive primary care lifestyle support to roughly $15,000 per QALY for behavioral programs and up to $8,000 per QALY for semaglutide in one scenario, showing that higher-priced medication and program options can still be evaluated as cost effective depending on assumptions.
05 · Category
Industry Trends5 stats
01
In a real-world study, adherence rates to anti-obesity medications were around 50% at 6 months
02
In a claims study, 1-year discontinuation rates for anti-obesity drugs were around 60% to 70%
03
From 2018 to 2022, prescriptions for GLP-1 and related obesity drugs increased by more than 3x in the U.S. (claims analysis)
04
The FDA required a boxed warning for deep vein thrombosis/pulmonary embolism risk for some obesity medicines (risk category included in labeling)
05
In 2021, the FDA received over 100,000 reports of adverse events associated with drugs labeled for weight loss (FAERS cumulative)
Interpretation
Industry Trends Interpretation
Even as U.S. prescriptions for GLP 1 and related obesity drugs more than tripled from 2018 to 2022, adherence still bottoms out at about 50% by 6 months and 1 year discontinuation reaches roughly 60% to 70%, with the FDA receiving over 100,000 adverse event reports in 2021.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Nathan Caldwell. (2026, February 13). Weight Loss Industry Statistics. Gitnux. https://gitnux.org/weight-loss-industry-statistics
MLA
Nathan Caldwell. "Weight Loss Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/weight-loss-industry-statistics.
Chicago
Nathan Caldwell. 2026. "Weight Loss Industry Statistics." Gitnux. https://gitnux.org/weight-loss-industry-statistics.
Sources & references
63 datasets cited across this report · attribution is report-level
+42 additional datasets cited (not shown individually)